<DOC>
	<DOCNO>NCT01688024</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety mitomycin C treatment primary sclerosing cholangitis ( PSC ) .</brief_summary>
	<brief_title>Mitomycin C Therapy Patients With Primary Sclerosing Cholangitis</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Ages 18 old Previously establish diagnosis primary sclerosing cholangitis American Society Anesthesiologists class 4 great Serum creatinine &gt; = 1.7 mg/dL , eGFR &lt; = 30 mL/min , dialysis dependence Serum hemoglobin &lt; = 7 g Left ventricular ejection fraction &lt; = 30 % Dyspnea minimal exertion ( supplemental oxygen dependence ) History bone marrow disease Prior recipient organ transplantation Ongoing chemotherapy Obstruction upper GI tract Pregnant lactating Inability provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>mitomycin C</keyword>
</DOC>